Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IsoTis takes bone graft to US dental market:

This article was originally published in Clinica

Executive Summary

IsoTis OrthoBiologics has received US FDA 510(k) clearance to use its advanced synthetic bone graft material, OsSatura BCP, in dental applications. The company, which already markets in the US demineralised bone matrix (DBM) product range, said that the dental field represented a strong area of growth for IsoTis. The dental arena accounts for around 10% of the Lausanne, Switzerland firm's sales. The new dental product is composed of approximately 80% hydroxyapatite and 20% ss-tricalcium phosphate.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059674

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel